There’s so much to like about this news release. In particular, it does a wonderful and economical job summarizing the benefits of the drugs being studied. It provides the numbers in both absolute and relative terms, for example. But it skimps on some of the details, chiefly the costs of the drugs, that the funder of the study makes one of the drugs in question, and whether the drugs are experimental or on the market.
Osteoporosis is a well-known risk factor for fracture, especially among older women. It can also be screened for with x-rays that measure bone density. A number of different treatments exist for individuals with osteoporosis and this news release presents data from a published study in JAMA.
For most individuals with osteoporosis, calcium and vitamin D supplements are recommended if dietary consumption isn’t adequate. First-line medications to decrease fracture risk is a group called the bisphosphonates. These medicines have been around for several decades and are usually taken by mouth on a weekly basis or by injection once a year. For individuals who are at particularly high risk, including those who have had a fracture while taking a bisphosphonate, second-line therapy is considered. These medicines include teriparatides that are given as a daily injection under the skin. The current study compares a new version of this class of drug, abaloparatide, to placebo and teriparatide. As a related editorial highlights, there are a number of effective medicines to prevent fractures in those with osteoporosis and they are probably under-used. For most individuals, use of existing oral medicines should be the focus of initial treatment. The current study focuses on giving patients who didn’t respond to the initial therapy or other high risk individuals another option.
There is no discussion of costs in the release. At a minimum it could have mentioned the cost of the existing FDA-approved comparator drug.
High in the release, the benefits of the drugs being studied and the placebo being compared are quantified clearly in both relative and absolute terms. Readers can see clearly that we are talking about quite a small group of people who saw benefits from either drug compared to the rather large group of women who were studied.
Most of the data presented was absolute risk which was excellent. This shows the benefit as well as the fact that most patients didn’t have a fracture regardless of which treatment was given.
The release says that there were no significant differences in harms seen between the drugs and the placebo without describing all the side effects. But it also mentions that hypercalcemia (elevated calcium level) was lower with the new agent compared to the existing comparator drug. While this was not explained in depth, we’ll give the release the benefit of the doubt for this brief mention of harms.
The story does a nice, succinct job explaining how the study was constructed, how many people participated, and other important details.
There is no disease mongering in the release.
To its credit the release quotes two people not associated with the study from an accompanying editorial and explains that the study was funded by Radius Health. But it does not make it clear whether Radius Health is involved in making an osteoporosis drug. Instead, the release directs readers to the full study (which is behind a firewall and available only to journal subscribers) for information on financial disclosures. The disclosure shows that several of the researchers, notably Paul Miller, MD, the corresponding author noted in the release, is a member of the scientific advisory board for Radius Health and several other pharmaceutical companies, and received research grants from Radius Health and a dozen other pharmaceutical sponsors. We think this information was important enough to include in the release itself.
The study itself was a comparison of two drugs and a placebo. The release explains that. The only thing that would have been better than this would have been an explanation of other ways the condition is treated.
This treatment is often viewed as a second-line one because it involves the inconvenience of injections under the skin. For most individuals, there are simpler oral treatments that are effective and have a long track record. The treatments studied here are for those with higher risks, especially those who did not respond to or did not tolerate the existing therapy.
The release does not make it clear whether the drugs being studied are on the market.
The release does not make the novelty of the findings clear. In the second paragraph, the piece discusses how this medicine works and that the study is comparing a new medicine with one already available. But what isn’t stated is why we need a new medicine. Isn’t the existing one good enough?
There is no unjustifiable language in the release.
Systematic, Criteria-Driven
A great read on this weekend’s NYT claims of a cure for Type 1.
Cure for Type 1 diabetes? We’ve been down this road before with NY Times https://www.healthnewsreview.org/2021/11/cure-for-type-1-diabetes-weve-been-down-this-road-before-with-ny-times/
"But it is the framing and the emphasis of the #journalism by a leading science journalist at a leading newspaper that demands scrutiny. It has an impact on readers and on sick people that may cause harm by promoting false hope about extremely preliminary research"
👍👏💪 truth https://twitter.com/garyschwitzer/status/1465399358137024518
Why we should still miss healthnewsreview. https://twitter.com/garyschwitzer/status/1465399358137024518
Comments
Please note, comments are no longer published through this website. All previously made comments are still archived and available for viewing through select posts.
Our Comments Policy
But before leaving a comment, please review these notes about our policy.
You are responsible for any comments you leave on this site.
This site is primarily a forum for discussion about the quality (or lack thereof) in journalism or other media messages (advertising, marketing, public relations, medical journals, etc.) It is not intended to be a forum for definitive discussions about medicine or science.
We will delete comments that include personal attacks, unfounded allegations, unverified claims, product pitches, profanity or any from anyone who does not list a full name and a functioning email address. We will also end any thread of repetitive comments. We don”t give medical advice so we won”t respond to questions asking for it.
We don”t have sufficient staffing to contact each commenter who left such a message. If you have a question about why your comment was edited or removed, you can email us at feedback@healthnewsreview.org.
There has been a recent burst of attention to troubles with many comments left on science and science news/communication websites. Read “Online science comments: trolls, trash and treasure.”
The authors of the Retraction Watch comments policy urge commenters:
We”re also concerned about anonymous comments. We ask that all commenters leave their full name and provide an actual email address in case we feel we need to contact them. We may delete any comment left by someone who does not leave their name and a legitimate email address.
And, as noted, product pitches of any sort – pushing treatments, tests, products, procedures, physicians, medical centers, books, websites – are likely to be deleted. We don”t accept advertising on this site and are not going to give it away free.
The ability to leave comments expires after a certain period of time. So you may find that you’re unable to leave a comment on an article that is more than a few months old.
You might also like